TY - JOUR
T1 - The interaction between metformin and physical activity on postprandial glucose and glucose kinetics
T2 - a randomised, clinical trial
AU - Pilmark, Nanna S.
AU - Lyngbæk, Mark
AU - Oberholzer, Laura
AU - Elkjær, Ida
AU - Petersen-Bønding, Christina
AU - Kofoed, Katja
AU - Siebenmann, Christoph
AU - Kellenberger, Katja
AU - van Hall, Gerrit
AU - Abildgaard, Julie
AU - Ellingsgaard, Helga
AU - Lauridsen, Carsten
AU - Ried-Larsen, Mathias
AU - Pedersen, Bente K.
AU - Hansen, Katrine B.
AU - Karstoft, Kristian
PY - 2021
Y1 - 2021
N2 - Aims/hypothesis The aim of this parallel-group, double-blinded (study personnel and participants), randomised clinical trial was to assess the interaction between metformin and exercise training on postprandial glucose in glucose-intolerant individuals.Methods Glucose-intolerant (2 h OGTT glucose of 7.8-11.0 mmol/l and/or HbA(1c) of 39-47 mmol/mol [5.7-6.5%] or glucose-lowering-medication naive type 2 diabetes), overweight/obese (BMI 25-42 kg/m(2)) individuals were randomly allocated to a placebo study group (PLA,n = 15) or a metformin study group (MET,n = 14), and underwent 3 experimental days: BASELINE (before randomisation), MEDICATION (after 3 weeks of metformin [2 g/day] or placebo treatment) and TRAINING (after 12 weeks of exercise training in combination with metformin/placebo treatment). Training consisted of supervised bicycle interval sessions with a mean intensity of 64% of Watt(max)for 45 min, 4 times/week. The primary outcome was postprandial glucose (mean glucose concentration) during a mixed meal tolerance test (MMTT), which was assessed on each experimental day. For within-group differences, a group x time interaction was assessed using two-way repeated measures ANOVA. Between-group changes of the outcomes at different timepoints were compared using unpaired two-tailed Student'sttests.Results Postprandial glucose improved from BASELINE to TRAINING in both the PLA group and the MET group ( increment PLA: -0.7 [95% CI -1.4, 0.0] mmol/l,p = 0.05 and increment MET: -0.7 [-1.5, -0.0] mmol/l,p = 0.03), with no between-group difference (p = 0.92). In PLA, the entire reduction was seen from MEDICATION to TRAINING (-0.8 [-1.3, -0.1] mmol/l,p = 0.01). Conversely, in MET, the entire reduction was observed from BASELINE to MEDICATION (-0.9 [-1.6, -0.2] mmol/l,p = 0.01). The reductions in mean glucose concentration during the MMTT from BASELINE to TRAINING were dependent on differential time effects: in the PLA group, a decrease was observed at timepoint (t) = 120 min (p = 0.009), whereas in the MET group, a reduction occurred at t = 30 min (p <0.001). (V) over dotO(2peak)increased 15% (4.6 [3.3, 5.9] ml kg(-1) min(-1),p <0.0001) from MEDICATION to TRAINING and body weight decreased (-4.0 [-5.2, -2.7] kg,p <0.0001) from BASELINE to TRAINING, with no between-group differences (p = 0.7 andp = 0.5, respectively).Conclusions/interpretation Metformin plus exercise training was not superior to exercise training alone in improving postprandial glucose. The differential time effects during the MMTT suggest an interaction between the two modalities.
AB - Aims/hypothesis The aim of this parallel-group, double-blinded (study personnel and participants), randomised clinical trial was to assess the interaction between metformin and exercise training on postprandial glucose in glucose-intolerant individuals.Methods Glucose-intolerant (2 h OGTT glucose of 7.8-11.0 mmol/l and/or HbA(1c) of 39-47 mmol/mol [5.7-6.5%] or glucose-lowering-medication naive type 2 diabetes), overweight/obese (BMI 25-42 kg/m(2)) individuals were randomly allocated to a placebo study group (PLA,n = 15) or a metformin study group (MET,n = 14), and underwent 3 experimental days: BASELINE (before randomisation), MEDICATION (after 3 weeks of metformin [2 g/day] or placebo treatment) and TRAINING (after 12 weeks of exercise training in combination with metformin/placebo treatment). Training consisted of supervised bicycle interval sessions with a mean intensity of 64% of Watt(max)for 45 min, 4 times/week. The primary outcome was postprandial glucose (mean glucose concentration) during a mixed meal tolerance test (MMTT), which was assessed on each experimental day. For within-group differences, a group x time interaction was assessed using two-way repeated measures ANOVA. Between-group changes of the outcomes at different timepoints were compared using unpaired two-tailed Student'sttests.Results Postprandial glucose improved from BASELINE to TRAINING in both the PLA group and the MET group ( increment PLA: -0.7 [95% CI -1.4, 0.0] mmol/l,p = 0.05 and increment MET: -0.7 [-1.5, -0.0] mmol/l,p = 0.03), with no between-group difference (p = 0.92). In PLA, the entire reduction was seen from MEDICATION to TRAINING (-0.8 [-1.3, -0.1] mmol/l,p = 0.01). Conversely, in MET, the entire reduction was observed from BASELINE to MEDICATION (-0.9 [-1.6, -0.2] mmol/l,p = 0.01). The reductions in mean glucose concentration during the MMTT from BASELINE to TRAINING were dependent on differential time effects: in the PLA group, a decrease was observed at timepoint (t) = 120 min (p = 0.009), whereas in the MET group, a reduction occurred at t = 30 min (p <0.001). (V) over dotO(2peak)increased 15% (4.6 [3.3, 5.9] ml kg(-1) min(-1),p <0.0001) from MEDICATION to TRAINING and body weight decreased (-4.0 [-5.2, -2.7] kg,p <0.0001) from BASELINE to TRAINING, with no between-group differences (p = 0.7 andp = 0.5, respectively).Conclusions/interpretation Metformin plus exercise training was not superior to exercise training alone in improving postprandial glucose. The differential time effects during the MMTT suggest an interaction between the two modalities.
KW - Exercise
KW - Impaired glucose tolerance
KW - Interaction
KW - Metformin
KW - Mixed meal tolerance test
KW - Postprandial glucose
KW - Prediabetes
KW - Stable isotope glucose tracers
KW - Training
KW - TYPE-2 DIABETES-MELLITUS
KW - GLYCEMIC CONTROL
KW - INSULIN SENSITIVITY
KW - EXERCISE
KW - INDIVIDUALS
KW - PEOPLE
KW - MASS
KW - AMPK
U2 - 10.1007/s00125-020-05282-6
DO - 10.1007/s00125-020-05282-6
M3 - Journal article
C2 - 32979074
VL - 64
SP - 397
EP - 409
JO - Diabetologia
JF - Diabetologia
SN - 0012-186X
ER -